Experimental Study of Efficiency of Tertapeptide Lysil-Glutamyl-Aspartyl- Proline Using the Model of Benign Prostatic Hyperplasia

DOI: 10.4236/mri.2014.33013   PDF   HTML   XML   3,436 Downloads   3,860 Views  

Abstract

Experimental evaluation of efficiency of a new prostatotropic medication tertapeptide lysil-glutamyl-aspartyl-proline (Lys-Glu-Asp-Pro) in treatment of benign prostatic hyperplasia was performed in Wistar rats. The efficiency of the medication was compared with that one of injections of the Serenoa repensextract. The investigation showed the statistically significant decrease in the square of the epithelium of acini. The same effect of similar severity was obtained when the Serenoa repens extract was applied. Tertapeptide Lys-Glu-Asp-Pro, in difference from Serenoa repens extract, also resulted in weight loss and volume decrease of the prostate gland.

Share and Cite:

Borovskaya, T. , Fomina, T. , Shchemerova, J. , Poluektova, M. , Vychuzhanina, A. , Kamalova, S. and Ermolaeva, L. (2014) Experimental Study of Efficiency of Tertapeptide Lysil-Glutamyl-Aspartyl- Proline Using the Model of Benign Prostatic Hyperplasia. Modern Research in Inflammation, 3, 108-112. doi: 10.4236/mri.2014.33013.

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1] Kirby, R. (2011) Improving Lower Urinary Tract Symptoms in BPH. Practitioner, 255, 15-19.
[2] Stroup, S.P., Palazzi-Churas, K., Kopp, R.P. and Parsons, J.K. (2012) Trends in Adverse Events of Benign Prostatic Hyperplasia (BPH). BJU International, 109, 84-87.
http://dx.doi.org/10.1111/j.1464-410X.2011.10250.x
[3] Vertkin, A.L., Rodukova, I.S., Galkin, I.V. and Arinina, E.N. (2009) Not Just a Prostate: Problems of Benign Prostatic Hyperplasia in Elderly. Pharmateca, 9, 50-55.
[4] Oelke, M., Kuczyk, M.A. and Herrmann, T.R. (2009) Medikamentose Therapie der Benignen Prostatahyperplasie. Urologe, 48, 1365-1377. http://dx.doi.org/10.1007/s00120-009-2141-y
[5] Carraro, J.C., Raynaud, J.R., Koch, G., et al. (1996) Comparison of Phytotherapy (Permixon) with Finasteride in Treatment of Benign Prostatic Hyperplasia: A Randomized International Study of 1098 Patients. Prostate, 29, 231-240. http://dx.doi.org/10.1002/(SICI)1097-0045(199610)29:4<231::AID-PROS4>3.0.CO;2-E
[6] Van Coppenolle, F., Le Bourhis, X., Carpentier, F., Delaby, G., Cousse, H., Raynaud, J.P., Dupouy, J.P. and Prevarskaya, N. (2000) Pharmacological Effects of Lipidosterolic Extract of Serenoa repens (Permixon) on Rat Prostate Hyperplasia Induced by Hyperprolactinemia: Comparison with Finasteride. Prostate, 43, 49-58.
http://dx.doi.org/10.1002/(SICI)1097-0045(20000401)43:1<49::AID-PROS7>3.0.CO;2-J
[7] Borovskaya, T.G., Pakhomova, A.V., Vychuzhanina, A.V., Poluektova, M.T. and Fomina, T.I. (2013) Experimental Studying of the Drug Efficiency Prostamax in the Therapy of Chronic Aseptic Prostatitis and Its Complications. Modern Research in Inflammation, 2, 54-58.
[8] Marks, L.S., Epstein, J.I., Partin, A.W., Simon, I., et al. (2000) Effects of a Saw Palmetto Herbal Blend in Men with Symptomatic Benign Prostatic Hyperplasia. Journal of Urology, 163, 1451-1456.
http://dx.doi.org/10.1016/S0022-5347(05)67641-0
[9] Bespalov, V.G., Murazov, J.G., Kuzhanov, A.A. and Semenov, A.L. (2013) Comparative Study of Prostatotropic Effects of Coniferous Provitamin Concentrate and Extract of Serenoa repens Based on the Model of Benign Prostatic Hyperplasia in Rats. Exp Clin Urology, 2, 30-34.
[10] Borovskaya, T.G., Fomina, T.I., Ermolaeva, L.A., Vychuzhanina, A.V., Pakhomova, A.V., Poluektova, M.E. and Shchemerova, Y.A. (2013) Comparative Evaluation of the Efficiency of Prostatotropic Agents of Natural Origin in Experimental Benign Prostatic Hyperplasia. Bulletin of Experimental Biology and Medicine, 155, 73-77. http://dx.doi.org/10.1007/s10517-013-2081-9
[11] Volkov, A.A., Voronova, O.V., Petrichko, M.I., Budnik, N.V. and Dukhin, A.R. (2012) Morphological Alterations of Prostate Tissue, upon Dutasteride Therapy Influence. Fundamental Research, 15, 36-39.

  
comments powered by Disqus

Copyright © 2020 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.